{"id":"NCT00934544","sponsor":"Novartis Pharmaceuticals","briefTitle":"Controlled Myelofibrosis Study With Oral Janus-associated Kinase (JAK) Inhibitor Treatment-II: The COMFORT-II Trial","officialTitle":"A Randomized Study of Ruxolitinib Tablets Compared to Best Available Therapy in Subjects With Primary Myelofibrosis, Post-Polycythemia Vera-Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-07-01","primaryCompletion":"2015-03-04","completion":"2015-03-04","firstPosted":"2009-07-08","resultsPosted":"2012-05-30","lastUpdate":"2019-08-19"},"enrollment":219,"design":{"allocation":"RANDOMIZED","model":"CROSSOVER","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Myelofibrosis"],"interventions":[{"type":"DRUG","name":"Ruxolitinib","otherNames":[]},{"type":"DRUG","name":"Best Available Therapy (BAT)","otherNames":[]}],"arms":[{"label":"Ruxolitinib","type":"EXPERIMENTAL"},{"label":"Best Available Therapy (BAT)","type":"ACTIVE_COMPARATOR"}],"summary":"This was an open label, randomized study comparing the efficacy and safety of randomized 2:1 Ruxolitinib tablets versus best-available therapy, as selected by the investigator. The purpose was to compare the efficacy, safety and tolerability of Ruxolitinib (INC424/INCB018424) given twice daily to the best-available therapy, in subjects with primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (PPV-MF) or post essential thrombocythemia myelofibrosis (PET-MF).","primaryOutcome":{"measure":"Percentage of Participants With at Least 35% Reduction in Spleen Volume From Baseline at Week 48","timeFrame":"Baseline, Week 48","effectByArm":[{"arm":"Ruxolitinib","deltaMin":28.5,"sd":null},{"arm":"Best Available Therapy (BAT)","deltaMin":0,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":8},"locations":{"siteCount":61,"countries":["Austria","Belgium","France","Germany","Italy","Netherlands","Spain","Sweden","United Kingdom"]},"refs":{"pmids":["28962635","26380150","26069290","24174625","24056820","23911705","22375970"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":51,"n":146},"commonTop":["Thrombocytopenia","Anaemia","Oedema peripheral","Diarrhoea","Asthenia"]}}